These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 11157906)

  • 1. In vitro activity of new quinolones against Clostridium difficile.
    Alonso R; Peláez T; González-Abad MJ; Alcalá L; Muñoz P; Rodríguez-Créixems M; Bouza E
    J Antimicrob Chemother; 2001 Feb; 47(2):195-7. PubMed ID: 11157906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates.
    Wilcox MH; Fawley W; Freeman J; Brayson J
    J Antimicrob Chemother; 2000 Oct; 46(4):551-6. PubMed ID: 11020251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
    Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
    Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp.
    Dubois J; St-Pierre C
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():41-6. PubMed ID: 10824031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly antibiotic-resistant Clostridium difficile isolates from Iranian patients.
    Baghani A; Ghourchian S; Aliramezani A; Yaseri M; Mesdaghinia A; Douraghi M
    J Appl Microbiol; 2018 Nov; 125(5):1518-1525. PubMed ID: 29957893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of four fluoroquinolones against clinical isolates of Pseudomonas aeruginosa determined by the E test.
    Swiatlo E; Moore E; Watt J; McDaniel LS
    Int J Antimicrob Agents; 2000 Jun; 15(1):73-6. PubMed ID: 10856680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activity of gemifloxacin.
    King A; May J; French G; Phillips I
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():1-12. PubMed ID: 10824026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
    Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Activity of new quinolones against clinical isolates of Corynebacterium species].
    Yagüe Guirao G; Martínez-Toldos MC; Mora Peris B; López Domínguez R; Romero Otero M; Muñoz Bellido JL; Segovia Hernández M
    Rev Esp Quimioter; 2000 Sep; 13(3):267-70. PubMed ID: 11086275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Clostridium difficile-associated diarrhea with a drug formulary change in preferred fluoroquinolones.
    Walbrown MA; Aspinall SL; Bayliss NK; Stone RA; Cunningham F; Squier CL; Good CB
    J Manag Care Pharm; 2008; 14(1):34-40. PubMed ID: 18240880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs.
    Ruiz-Serrano MJ; Alcalá L; Martínez L; Díaz M; Marín M; González-Abad MJ; Bouza E
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2567-8. PubMed ID: 10952620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activities of 13 quinolones by three susceptibility testing methods against a collection of Haemophilus influenzae isolates with different levels of susceptibility to ciprofloxacin: evidence for cross-resistance.
    Pérez-Vázquez M; Román F; Varela MC; Cantón R; Campos J
    J Antimicrob Chemother; 2003 Jan; 51(1):147-51. PubMed ID: 12493800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
    Adams DA; Riggs MM; Donskey CJ
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2674-8. PubMed ID: 17562807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of OPT-80 against Clostridium difficile.
    Ackermann G; Löffler B; Adler D; Rodloff AC
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2280-2. PubMed ID: 15155234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibility of anaerobes to quinolones in the United States.
    Hecht DW; Wexler HM
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S2-8. PubMed ID: 8953099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
    Barry AL; Fuchs PC
    J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
    Bauernfeind A
    J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ciprofloxacin and Clostridium difficile-associated diarrhoea.
    Golledge CL; Carson CF; O'Neill GL; Bowman RA; Riley TV
    J Antimicrob Chemother; 1992 Aug; 30(2):141-7. PubMed ID: 1399923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of supplemented Brucella agar and modified Clostridium difficile agar for antimicrobial susceptibility testing of Clostridium difficile.
    Kim GH; Kim J; Pai H; Kang JO
    Ann Lab Med; 2014 Nov; 34(6):439-45. PubMed ID: 25368819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.